Retinal specialists have a new therapy in their armoury: on January 24th 2007, the European Commission approved ranibizumab (Lucentis, Novartis) for the treatment of patients with wet age-related macular degeneration (AMD).
Industry updates from Floretina ICOOR 2024
The annual meeting brought fourth announcements and insights from companies in the retina care space
PHOTON Results and Their Relation to DME Patients in Your Practice
John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.
New wet AMD therapeutics seek to improve visual outcomes beyond the current standard of care
Breakthrough technologies are raising the ceiling for functional visual outcomes
PULSAR Results and Their Relation to nAMD Patients in Your Practice
John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.
Adapting our understanding of cerebral visual impairment
The differential recruitment of the dorsal and ventral visual streams
Ethnic background has an impact on glaucoma outcomes
Gauging patient perceptions in an ethnically diverse UK cohort